A new medical strategy shows how science, politics, and economics now move together. Russia has taken a bold step into personalized cancer care with the first use of its mRNA vaccine Neooncovac on a patient from the Kursk region. The treatment took place at the National Medical Research Center for Radiology in Moscow and marks a shift from mass medicine to patient-specific therapy. The project partners with three organizations, which include the Russian Ministry of Health, the Gamaleya National Research Center for Epidemiology and Microbiology, and the Blokhin National Medical Research Center of Oncology. The initiative also serves to advance a broader objective. Russia aims to develop a domestic medical system that enables it to compete with Western companies like Moderna and BioNTech and that eliminates their need for foreign supply chains.

Russia’s Shift to Personalized mRNA Cancer Vaccines

The scientific foundation of the project centers on mRNA research. The basic idea of the project delivers its most profound impact through its simple execution. Through their medical practice, doctors obtain tumor samples from patients, which they use to study the tumor’s genetic structure. They identify unique markers called neoantigens that exist only on cancer cells. Scientists create a personalized vaccine using the data, which trains the immune system to locate and eliminate those specific cells.

According to early reports from the National Medical Research Radiological Center, the process can take three to four months. The treatment may include several doses along with other forms of immunotherapy. The present methods of cancer treatment through chemotherapy and radiation pose a significant obstacle because they destroy both cancer cells and healthy body parts.

Russia is not relying on one method alone. Alongside Neooncovac, researchers are developing Enteromix and Oncopept. These target cancers include........

© Paradigm Shift